| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ABCC4 genetic polymorphism may indirectly regulate disposition of capecitabine metabolite in colorectal cancer patients
|
Masuo, Yusuke
|
|
|
61 |
S |
p.
|
artikel
|
| 2 |
Absolute bioavailability, biotransformation, and excretion of the bruton tyrosine kinase inhibitor TL-895 in healthy human subjects
|
Podoll, Terry
|
|
|
61 |
S |
p.
|
artikel
|
| 3 |
Absolute bioavailability, biotransformation, and excretion of the mouse double minute 2 inhibitor navtemadlin in healthy human subjects
|
Podoll, Terry
|
|
|
61 |
S |
p.
|
artikel
|
| 4 |
Absorption, distribution, metabolism and excretion studies following a single oral dose administration of onvansertib to rats
|
Shinde, Aparna
|
|
|
61 |
S |
p.
|
artikel
|
| 5 |
Abstract withdrawn
|
|
|
|
61 |
S |
p.
|
artikel
|
| 6 |
A case study for visualizing oligonucleotide therapeutics distribution in rat organs using MALDI mass spectrometry imaging
|
Aikawa, Hiroaki
|
|
|
61 |
S |
p.
|
artikel
|
| 7 |
A case study: The extrahepatic clearance contributing to the in vitro in vivo extrapolation disconnect of an internal novel chemical entity A1
|
Zhong, Guo
|
|
|
61 |
S |
p.
|
artikel
|
| 8 |
A combined quantitative and qualitative DMPK assay using pooled samples for increased throughput in macrocylic peptide drug development
|
Hackbusch, Sven
|
|
|
61 |
S |
p.
|
artikel
|
| 9 |
A comprehensive platform for evaluating the in vitro CYP reaction phenotyping of New Molecular Entities (NME)
|
Jiang, Lifang
|
|
|
61 |
S |
p.
|
artikel
|
| 10 |
Addressing common metabolism problems in drug discovery with in silico methods
|
Barr, Daniel
|
|
|
61 |
S |
p.
|
artikel
|
| 11 |
Addressing the challenges of determining fraction metabolized for low turnover drugs – An update from the quantitative fraction metabolized working group of the IQ consortium
|
Cohen, Lawrence
|
|
|
61 |
S |
p.
|
artikel
|
| 12 |
Advances in enabling IVIVE and enzyme phenotyping of low clearance compounds
|
Patel, Mitesh
|
|
|
61 |
S |
p.
|
artikel
|
| 13 |
A four-compartment stomach representative of the FED gastric pH profile in physiologically-based pharmacokinetic models can improve predictive accuracy of food effects on oral drug absorption
|
Cheng, Lisa
|
|
|
61 |
S |
p.
|
artikel
|
| 14 |
Age and sex influence the pharmacokinetics and brain distribution of REC-3599, a selective inhibitor of protein kinase C, in rats
|
Manda, Vamshi
|
|
|
61 |
S |
p.
|
artikel
|
| 15 |
A hybrid trial approach by combining 13C8-lableded and radiolabeled brilaroxazine to assess absolute bioavailability and hame in a single clinical trial
|
Shen, Li
|
|
|
61 |
S |
p.
|
artikel
|
| 16 |
AI-Based feature generation for molecular design
|
Mizuno, Tadahaya
|
|
|
61 |
S |
p.
|
artikel
|
| 17 |
AI platform to accelerate drug discovery
|
Okuno, Yasushi
|
|
|
61 |
S |
p.
|
artikel
|
| 18 |
Alleviating mycophenolic acid-induced toxicity in the GI tract using wogonin and chrysin
|
Du, Ting
|
|
|
61 |
S |
p.
|
artikel
|
| 19 |
Alteration in intercellular lipid composition of stratum corneum in Goto-Kakizaki rats: A model of type 2 diabetes with an increased fentanyl release ratio from the transdermal formulation
|
Mizuno, Satoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 20 |
Alteration of blood brain-barrier proteome in various conditions
|
Ohtsuki, Sumio
|
|
|
61 |
S |
p.
|
artikel
|
| 21 |
Alteration of renal-liver-cardiac interactions linked by circadian machinery underlies chronic kidney disease-associated cardiac inflammation and fibrosis
|
Yoshida, Yuya
|
|
|
61 |
S |
p.
|
artikel
|
| 22 |
Analysis of drug-endogenous substrate interactions using in vitro and in vivo methods
|
Sunakawa, Hiroki
|
|
|
61 |
S |
p.
|
artikel
|
| 23 |
Analysis of government regulation effectiveness based on phthalate risk assessment
|
Park, Seungyoung
|
|
|
61 |
S |
p.
|
artikel
|
| 24 |
Analysis of influx/efflux kinetics of metformin in Caco-2 cells
|
Kawabata, Kohei
|
|
|
61 |
S |
p.
|
artikel
|
| 25 |
Analytical methods for PK analysis of antibody drug conjugates
|
Haydock, Leah
|
|
|
61 |
S |
p.
|
artikel
|
| 26 |
Analytical validation of a genotyping technique for a single-nucleotide polymorphism to predict of the onset SJS/TEN in Japanese
|
Tsukagoshi, Eri
|
|
|
61 |
S |
p.
|
artikel
|
| 27 |
An evaluation of CYP and non-CYP reaction phenotyping study trends from 2000-2023: A cro perspective
|
Mueller, Tina
|
|
|
61 |
S |
p.
|
artikel
|
| 28 |
A new indicator for detecting weak inducers by 4Β-Hydroxycholesterol as a biomarker of CYP3A4 induction, and protocol for handling clinical samples
|
Taya, Yuki
|
|
|
61 |
S |
p.
|
artikel
|
| 29 |
A new model to predict drug enterohepatic recirculation in healthy humans with nalbuphine as a model drug
|
Korzekwa, Ken
|
|
|
61 |
S |
p.
|
artikel
|
| 30 |
Animal species differences in the amiloride transport function of SLC19A3
|
Yamashiro, Takahiro
|
|
|
61 |
S |
p.
|
artikel
|
| 31 |
An improved sample preparation and analysis procedure for estradiol LC-MS/MS quantification
|
Johns, Michael
|
|
|
61 |
S |
p.
|
artikel
|
| 32 |
Antisense oligonucleotides’ metabolite identification using hydrophilic interaction liquid chromatography—High resolution mass spectrometry: Application for non-human primate study samples of tofersen
|
Liu, Ying
|
|
|
61 |
S |
p.
|
artikel
|
| 33 |
Application of a permeability-limited multi-compartment liver (PerMCL) model to predict zonal hepatocellular statin concentrations in metabolic dysfunction-associated steatohepatitis (MASH)
|
Murphy, William
|
|
|
61 |
S |
p.
|
artikel
|
| 34 |
Application of enteroid monolayers to evaluate potential pharmacokinetic oregano oil-drug interactions
|
O'Mahony, Eimear
|
|
|
61 |
S |
p.
|
artikel
|
| 35 |
Application of proteomic correlation profiling technique based on proteomic data to identify enzymes involved in metabolism of drugs of concern
|
Kudo, Takashi
|
|
|
61 |
S |
p.
|
artikel
|
| 36 |
A rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantifying the metabolites of seven major probe substrates in human liver microsomes
|
Li, Xiaotong
|
|
|
61 |
S |
p.
|
artikel
|
| 37 |
ARE Δ9-tetrahydrocannabinol and its major metabolites substrates or inhibitors of the human hepatic and placental solute-carrier transporters?
|
Chen, Xin
|
|
|
61 |
S |
p.
|
artikel
|
| 38 |
A retrospective comparison of the PK profiles of lipid 5, the ionizable lipid in LNP2, across rat, NHP, and human
|
Rowbottom, Chris
|
|
|
61 |
S |
p.
|
artikel
|
| 39 |
A sensitive and efficient LC-MS/MS method for creatinine-d5 analysis in in vitro OCT2 inhibition assay
|
Li, Xiaotong
|
|
|
61 |
S |
p.
|
artikel
|
| 40 |
A seven cytochrome P450 index substrate cocktail for clinical trials – Profiling the effects of clopidogrel and gemfibrozil on CYP enzymes and OATP1B1 biomarkers
|
Aurinsalo, Laura
|
|
|
61 |
S |
p.
|
artikel
|
| 41 |
A simple approach for facile determination of metabolic softspots of macrocyclic peptides based on metabolite genealogy information revealed in the metabolite profiles
|
Zhang, Haiying
|
|
|
61 |
S |
p.
|
artikel
|
| 42 |
Assess CYP450 induction by qRT-PCR quantificaiton of CYP450 mRNAs from Small Extracellular Vesicles (SEVS) derived from plasma
|
Xu, Shengjie
|
|
|
61 |
S |
p.
|
artikel
|
| 43 |
Assessing the ADME properties of belvarafenib (GDC-5573),a RAF inhibitor, in male rats
|
Zhao, Weiping
|
|
|
61 |
S |
p.
|
artikel
|
| 44 |
Assessing the first-pass effects of of felodipine with the small intestine-liver coupled microphysiological system
|
Nakai, Takaaki
|
|
|
61 |
S |
p.
|
artikel
|
| 45 |
Assessment of ADME and DDI for LNP-MRNA therapeutics
|
Ci, Lei
|
|
|
61 |
S |
p.
|
artikel
|
| 46 |
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab (lunsumiotm) using physiologically-based pharmacokinetic modeling
|
Ma, Fang
|
|
|
61 |
S |
p.
|
artikel
|
| 47 |
Assessment of integrated strategy for prodrug metabolic transformation in plasma: Statistical and analytical
|
Wang, Wei
|
|
|
61 |
S |
p.
|
artikel
|
| 48 |
Assessment of in vitro methods for UGT1A1 inhibition in recombinant isozyme
|
Wang, Ting-Yi
|
|
|
61 |
S |
p.
|
artikel
|
| 49 |
Assessment of moxifloxacin-induced QTC prolongaton in canine and nonhuman primate using a linear mixed effect modeling approach
|
Patel, Jaimini
|
|
|
61 |
S |
p.
|
artikel
|
| 50 |
Assessment of plasma protein binding of pegylated bilirubin: A Comparative study of rapid equilibrium dialysis and ultracentrifugation method
|
Park, Seo-jin
|
|
|
61 |
S |
p.
|
artikel
|
| 51 |
Assessment of unintentional effects on endangered species endemic to the Bonin Islands caused by deployment of anticoagulant rodenticide
|
Koide, Masashi
|
|
|
61 |
S |
p.
|
artikel
|
| 52 |
A tale of preclinical insights into bile salt homeostasis disruption in DILI
|
Lai, Yurong
|
|
|
61 |
S |
p.
|
artikel
|
| 53 |
Authenticity and adulteration of botanical natural products: Lessons from a decade of sourcing materials for scientific investigation
|
Cech, Nadja
|
|
|
61 |
S |
p.
|
artikel
|
| 54 |
Author Index
|
|
|
|
61 |
S |
p.
|
artikel
|
| 55 |
Automated workflow for Targeted Protein Degrader (TPD) metabolite identification using Collision-Induced Dissociation (CID) and Electron-Activated Dissociation (EAD)
|
Colquhoun, David
|
|
|
61 |
S |
p.
|
artikel
|
| 56 |
Availability of polydimethylsiloxane chip in evaluation of small intestinal absorption
|
Hoshi, Misa
|
|
|
61 |
S |
p.
|
artikel
|
| 57 |
Best practice of mitigating P-Glycoprotein liabilities in drug discovery - Assessment and prediction of P-GP mediated nonlinear PK, brain penetration, and interactions
|
Hirabayashi, Hideki
|
|
|
61 |
S |
p.
|
artikel
|
| 58 |
Bioanlaysis, biotransformation and pharmacokinetics of antibody-drug conjugate
|
Kishino, Yuki
|
|
|
61 |
S |
p.
|
artikel
|
| 59 |
Biopharmaceutical, pharmacokinetic, and activity profiling of a novel locally bioavailable selectivE COX-2 inhibitor for colorectal cancer prevention
|
Ma, Yong
|
|
|
61 |
S |
p.
|
artikel
|
| 60 |
Blood glucose control via oral Zn-insulin administration together with small intestine-permeable cyclic peptides in mouse models of diabetes mellitus
|
Chikamatsu, Shoma
|
|
|
61 |
S |
p.
|
artikel
|
| 61 |
Botanical-drug interactions: Blazing the trail using translational tools
|
Paine, Mary
|
|
|
61 |
S |
p.
|
artikel
|
| 62 |
Bridging targeted metabolomics to global proteomics approach to clarify ribavirin- induced resistance in breast cancer MCF-7 cells
|
Kawami, Masashi
|
|
|
61 |
S |
p.
|
artikel
|
| 63 |
Building an automated, high throughput in vitro ADME screening platform
|
Lusk, Sarah
|
|
|
61 |
S |
p.
|
artikel
|
| 64 |
Building robust human liver microsomal stability predictions: Leveraging inter- species correlation with rat data
|
Shah, Pranav
|
|
|
61 |
S |
p.
|
artikel
|
| 65 |
Cancer treatment methods in S-1 plus oxaliplatin utilizing renal function biomarkers with concurrent chronic kidney disease in rats
|
Tanaka, Takumi
|
|
|
61 |
S |
p.
|
artikel
|
| 66 |
Carrier-mediated uptake of capric acid in HEPG2 cells
|
Kitamura, Takuma
|
|
|
61 |
S |
p.
|
artikel
|
| 67 |
Cellular mechanisms of afatinib-induced fluid secretion in a 3D mouse enteroid model
|
Ariyadamrongkwan, Jutharat
|
|
|
61 |
S |
p.
|
artikel
|
| 68 |
CFT8634, a potent, selective and orally bioavailable BiDACTM degrader of BRD9, highlights the potential of C4T’S TORPEDO® platform to develop degraders with excellent drug-like properties against currently undruggable targets
|
Chaturvedi, Prasoon
|
|
|
61 |
S |
p.
|
artikel
|
| 69 |
Challenges and breakthroughs in the conduct of clinical cannabis studies
|
Vandrey, Ryan
|
|
|
61 |
S |
p.
|
artikel
|
| 70 |
Challenges and opportunities for improved prediction of CNS penetration across species using MDR1-overexpressing cells
|
Sóskuti, Emőka
|
|
|
61 |
S |
p.
|
artikel
|
| 71 |
Challenges of an active metabolite: The potential of disproportionate human exposure and the complex kinetics upon drug-drug interactions
|
Smukste, Inese
|
|
|
61 |
S |
p.
|
artikel
|
| 72 |
Change in transport function of drugs into the multicellular inner blood-retinal barrier spheroids under hypoxic culture with advanced glycation end-products
|
Akanuma, Shin-ichi
|
|
|
61 |
S |
p.
|
artikel
|
| 73 |
Changes in the expression of drug-metabolizing enzymes and transporters associated with decreased expression of CYP3A and MRP2
|
Fujino, Chieri
|
|
|
61 |
S |
p.
|
artikel
|
| 74 |
Characterization of age-dependent abundance of drug transporter proteins and conjugating enzymes in human hepatocytes: Implication for pediatric drug dosing
|
Thakur, Aarzoo
|
|
|
61 |
S |
p.
|
artikel
|
| 75 |
Characterization of an 3D-printed expandable drug delivery system for tofacitinib in beagle dogs
|
Kim, Keon
|
|
|
61 |
S |
p.
|
artikel
|
| 76 |
Characterization of 14C-Eltanexor metabolism and disposition in rats
|
Fan, Rong
|
|
|
61 |
S |
p.
|
artikel
|
| 77 |
Characterization of common DPYD single nucleotide variants on 5-fluorouracil catabolism in vitro
|
Cui, Elizabeth
|
|
|
61 |
S |
p.
|
artikel
|
| 78 |
Characterization of human immortalized cell-based blood-brain barrier spheroid models as a tool for brain vascular inflammation studies
|
Morio, Hanae
|
|
|
61 |
S |
p.
|
artikel
|
| 79 |
Characterization of long-lasting inhibition of amino acid transporter LAT1 by nanvuranlat (JPH203) in cholangiocellular carcinoma
|
Oka, Kiyoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 80 |
Characterization of pyrazinamide metabolism in vitro: Insights into the role of the aldehyde oxidase, and xanthine oxidase
|
Howlader, Saurav
|
|
|
61 |
S |
p.
|
artikel
|
| 81 |
Circulating biomarker discovery for mash
|
Zubair, Faizan
|
|
|
61 |
S |
p.
|
artikel
|
| 82 |
Circulating tumor cells kinetics after short- and long-term folfirinox and GEM/NAB-PTX chemotherapy in xenograft mouse models of human pancreatic cancer
|
Ito, Yukako
|
|
|
61 |
S |
p.
|
artikel
|
| 83 |
Clarifying metabolism of the natural product drug troxerutin in vitro and in vivo
|
Wang, Kai
|
|
|
61 |
S |
p.
|
artikel
|
| 84 |
Clinical significance of drug-drug interaction studies during therapeutic peptide drug development
|
Wang, Kai
|
|
|
61 |
S |
p.
|
artikel
|
| 85 |
Closing the translational gap: Human multi-tissue chip platform for predictive and mechanistic preclinical studies
|
Cirit, Murat
|
|
|
61 |
S |
p.
|
artikel
|
| 86 |
Cocaine modulates CYP3A4 in primary human macrophages in a donor-specific fashion
|
Williams, Dionna
|
|
|
61 |
S |
p.
|
artikel
|
| 87 |
Comparative analysis of pharmacokinetic characteristics for the in-situ albumin drug conjugate
|
Lim, Jeonghyeon
|
|
|
61 |
S |
p.
|
artikel
|
| 88 |
Comparative metabolite profiling and identification of GalNAc-conjugated siRNA, siRNA01, in plasma prepared with various anticoagulants, serum, and in vivo plasma using LC-UV-HRMS
|
Zhang, Hong
|
|
|
61 |
S |
p.
|
artikel
|
| 89 |
Comparative pharmacokinetic profiles of favipiravir alone and in combination with Thai herbal extract in rats
|
Junsaeng, Dhirarin
|
|
|
61 |
S |
p.
|
artikel
|
| 90 |
Comparative pharmacokinetics of andrographolide after repeated oral administration of andrographis paniculata formulation capsules in Beagles
|
Boonyarattanasoonthorn, Tussapon
|
|
|
61 |
S |
p.
|
artikel
|
| 91 |
Comparison of titer and signal-to-noise ratio for determination of anti-drug antibody magnitude in immunogenicity assessment of biopharmaceuticals by using anti-drug antibody reference panel
|
Ishii-Watabe, Akiko
|
|
|
61 |
S |
p.
|
artikel
|
| 92 |
Comphrehensive metabolite profiling of SHO0302 in human plasma, urine and feces using LC-HRMS and an advanced data processing workflow: Comparison with radiochromatographic analysis
|
Zhu, Mingshe
|
|
|
61 |
S |
p.
|
artikel
|
| 93 |
Complex drug-drug interactions: Study design and clinical interpretation
|
Vourvahis, Manoli
|
|
|
61 |
S |
p.
|
artikel
|
| 94 |
Computer aided metid for small molecules and peptide drugs
|
Zamora, Ismael
|
|
|
61 |
S |
p.
|
artikel
|
| 95 |
Confirmation of albumin-mediated effect on organic anion transporter 1/3 and its improvement to prediction of renal clearance
|
Feng Tan, Shawn Pei
|
|
|
61 |
S |
p.
|
artikel
|
| 96 |
Confounding effects of B-glucuronidase on UDP-Glucuronosyltransferase stability: Development of a modified metabolic stability assay to enable SAR for a discovery program
|
Glass, Sarah
|
|
|
61 |
S |
p.
|
artikel
|
| 97 |
Construction and functional of human BBB model derived from MDR1 gene- transfected human iPS cells in two- and three-dimensional culture plate
|
Kurosawa, Toshiki
|
|
|
61 |
S |
p.
|
artikel
|
| 98 |
Construction of functional evaluation system for human BCRP-mediated biliary excretion using adeno-associated virus
|
Yoshino, Shotaro
|
|
|
61 |
S |
p.
|
artikel
|
| 99 |
Construction of pbpk model for multiple tyrosine kinase inhibitor TSU-68 based on in vitro induction kinetics of CYP1A
|
Ohno, Yasuhiro
|
|
|
61 |
S |
p.
|
artikel
|
| 100 |
Contribution of MCT6 in regulating cellular accumulation of the n-acetylcysteine s- conjugate metabolite of cisplatin
|
Germakovski, Arthur
|
|
|
61 |
S |
p.
|
artikel
|
| 101 |
Coproporphyrin I as an in vitro fluorescent probe for measuring OATP1B1 activity
|
Hayden, Elizabeth
|
|
|
61 |
S |
p.
|
artikel
|
| 102 |
COVID-19 severity dysregulates the expression of clinically relevant drug processing genes
|
Nwabufo, Chukwunonso
|
|
|
61 |
S |
p.
|
artikel
|
| 103 |
CYP7A1 gene induction via SHP-dependent or independent mechanisms can increase the risk of drug-induced liver injury independent or in synergy with BSEP inhibition
|
Niu, Congrong
|
|
|
61 |
S |
p.
|
artikel
|
| 104 |
CYP Induction assays using 10-Donor pooled human hepatocytes
|
Li, Feng
|
|
|
61 |
S |
p.
|
artikel
|
| 105 |
Cytochrome P450 3A chemical inhibitors: Understanding selectivity in human liver microsomes for use in reaction phenotyping
|
Tseng, Elaine
|
|
|
61 |
S |
p.
|
artikel
|
| 106 |
Cytochrome P450 (CYP) phenotyping of aficamten, a next-in-class inhibitor of cardiac myosin, using human liver microsomes and human recombinant CYP enzymes
|
Sukhun, Rajaa
|
|
|
61 |
S |
p.
|
artikel
|
| 107 |
Defining the therapeutic window of BI-Specific T-cell engagers
|
Conner, Kip
|
|
|
61 |
S |
p.
|
artikel
|
| 108 |
Detection of hard electrophilic reactive metabolites formed from alicyclic amines using glutathione trapping
|
Miao, Xiusheng
|
|
|
61 |
S |
p.
|
artikel
|
| 109 |
Determination of drug-to-antibody ratio of T-DXD in plsama sample by LBA-LC-MS
|
Li, Li
|
|
|
61 |
S |
p.
|
artikel
|
| 110 |
Determination of steady state brain KP,UU of BIDAC(TM) degraders using chemical knock out animal models
|
Bahadduri, Praveen
|
|
|
61 |
S |
p.
|
artikel
|
| 111 |
Detoxbug – Biotransformation in black soldier fly larvae
|
Ivanova, Lada
|
|
|
61 |
S |
p.
|
artikel
|
| 112 |
Developing a novel rat physiologically based pharmacokinetic model to improve the prediction of concentration-time profiles
|
Gong, Yifan
|
|
|
61 |
S |
p.
|
artikel
|
| 113 |
Developing natural products as potential therapeutic agents
|
Soumyanath, Amala
|
|
|
61 |
S |
p.
|
artikel
|
| 114 |
Developing renal function evaluation for pediatric dose selection based on pharmacometric approach with renally eliminated drugs
|
Okada, Akira
|
|
|
61 |
S |
p.
|
artikel
|
| 115 |
Development and qualification of an in vitro assay to determine target mediated internalization of TREM2 receptor specific antibodies for TMDD assessment
|
Kraft, Thomas
|
|
|
61 |
S |
p.
|
artikel
|
| 116 |
Development and validation of PBPK models for predicting human pharmacokinetics of enavogliflozin
|
Jeong, Hyeon-Cheol
|
|
|
61 |
S |
p.
|
artikel
|
| 117 |
Development of a monolayer model derived from intestinal organoids to evaluate the effect of the mucus layer on drug absorption
|
Suzuki, Yukiko
|
|
|
61 |
S |
p.
|
artikel
|
| 118 |
Development of an in vitro Metabolic Dysfunction-Associated Steatohepatitis (MASH) model to study hepatic transporters
|
Kyburz, Sarina
|
|
|
61 |
S |
p.
|
artikel
|
| 119 |
Development of an in vitro platform for screening UGT inhibitors using human liver microsomes
|
Jiang, Lifang
|
|
|
61 |
S |
p.
|
artikel
|
| 120 |
Development of an in vitro test system for CYP inhibition studies using cryopreserved human hepatocytes and comparison with human liver microsomes
|
Szili, Noémi
|
|
|
61 |
S |
p.
|
artikel
|
| 121 |
Development of a novel LC-MS method for methylene blue and its application to the pharmacokinetic and brain penetration studies in mouse
|
Lee, Juwon
|
|
|
61 |
S |
p.
|
artikel
|
| 122 |
Development of a PAC-LC-MS/MS method for simultaneous quantification of mipomersen, its metabolites, and analogues in tissue samples
|
Sun, Yuchen
|
|
|
61 |
S |
p.
|
artikel
|
| 123 |
Development of a physiologically based pharmacokinetic model to assess potential causes for differences in simvastatin pharmacokinetics between Thais and Caucasians
|
Sakares, Watchara
|
|
|
61 |
S |
p.
|
artikel
|
| 124 |
Development of a strategy to prevent cisplatin-induced kidney injury by targeting mate-type transporters
|
Kanda, Masaya
|
|
|
61 |
S |
p.
|
artikel
|
| 125 |
Development of a super high-plex immunohistochemistry platform providing improved confidence in translational research
|
Nitta, Katsuaki
|
|
|
61 |
S |
p.
|
artikel
|
| 126 |
Development of a system to evaluate biliary excretion of drugs using human cholangiocyte organoid monolayers
|
Mizoi, Kenta
|
|
|
61 |
S |
p.
|
artikel
|
| 127 |
Development of dissolution evaluation system for drug absorption (V): Additional intestinal absorption module of in vitro 3D gastric emptying mmodel for orally disintegrating tablet
|
Tagawa, Kozo
|
|
|
61 |
S |
p.
|
artikel
|
| 128 |
Development of human glucuronide atlas and its application for identifying endogenous UGT substrates by a novel metabolomic-based DMET biomarker discovery (MDBD) approach
|
Bachhav, Namrata
|
|
|
61 |
S |
p.
|
artikel
|
| 129 |
Development of organoid-derived enterocytes from human iPS cells or biopsied tissue for pharmaceutical research
|
Mizuguchi, Hiroyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 130 |
Discovery of genetic biomarkers associated with antituberculosis drug-induced liver injury in the Korean population: Insights from nuclear and mitochondrial DNA variations
|
Hoa Pham, Thi Vinh
|
|
|
61 |
S |
p.
|
artikel
|
| 131 |
Discovery of PF-07817883, a second-generation oral SARS-CoV2 main protease inhibitor
|
Kalgutkar, Amit
|
|
|
61 |
S |
p.
|
artikel
|
| 132 |
Discovery, validation, and application of transporter endogenous biomarkers: A work of translation
|
Shen, Hong
|
|
|
61 |
S |
p.
|
artikel
|
| 133 |
Does cannabidiol (CBD) or delta-9-tetrahydrocannabinol (THC) induce drug metabolizing enzymes in human hepatocytes?
|
Balhara, Ankit
|
|
|
61 |
S |
p.
|
artikel
|
| 134 |
Does the flux competition method add significant value in species difference protein binding evaluation?
|
Wang, Jie
|
|
|
61 |
S |
p.
|
artikel
|
| 135 |
Downstream effects of protein degraders
|
Donovan, Katherine
|
|
|
61 |
S |
p.
|
artikel
|
| 136 |
Driving compound optimization in early discovery by implementing mechanistic pharmacokinetic and machine learning models
|
Wang, Wenyi
|
|
|
61 |
S |
p.
|
artikel
|
| 137 |
Drug-drug interaction of paclitaxel and TAS-119, a novel aurora a kinase inhibitor, mediated by organic anion transporting polypeptide 1B1
|
Yoshisue, Kunihiro
|
|
|
61 |
S |
p.
|
artikel
|
| 138 |
Drug-drug interaction studies of cortisol in cynomolgus monkeys by measuring cortisol, cortisol-D4, and their 6β-hydroxymetabolites in plasma
|
Nakanishi, Yasuharu
|
|
|
61 |
S |
p.
|
artikel
|
| 139 |
Drug-induced gastrointestinal toxicity due to disruption of the interinfluence between serotonin and gut microbiota
|
Asaji, Suguru
|
|
|
61 |
S |
p.
|
artikel
|
| 140 |
Drug read-out in untargeted metabolomics using a MS/MS library of drugs and metabolites propagated from metabolomics data repository
|
Kvitne, Kine
|
|
|
61 |
S |
p.
|
artikel
|
| 141 |
Efavirenz-induced heme protein induction and coproporphyrin levels: Insights from in vitro experiments and in vivo studies
|
Potzel, Leila
|
|
|
61 |
S |
p.
|
artikel
|
| 142 |
Effect of chitosan on curcumin stabilization
|
Dechayont, Bhanuz
|
|
|
61 |
S |
p.
|
artikel
|
| 143 |
Effect of cimetidine and dolutegravir on renal clearance of metformin and putative endogenous biomarkers for OCT2/MATE1/2K (1-NMN, M1A, and creatinine) in healthy subjects
|
Koishikawa, Tomoki
|
|
|
61 |
S |
p.
|
artikel
|
| 144 |
Effect of hepatic CYP3A4 ontogeny on drug exposure in children varies depending on the elimination pathways and its contribution to total drug clearance
|
Emoto, Chie
|
|
|
61 |
S |
p.
|
artikel
|
| 145 |
Effect of lipopolysaccharide on P-Glycoprotein at the inner blood-retinal barrier in vivo
|
Daikohara, Kiyotaka
|
|
|
61 |
S |
p.
|
artikel
|
| 146 |
Effect of lipoprotein binding and plasma dilution on the accuracy of ultracentrifugation method in plasma protein binding
|
Wang, Jie
|
|
|
61 |
S |
p.
|
artikel
|
| 147 |
Effect of substrates and inhibitors of breast cancer resistance protein on apixaban and rivaroxaban pharmacokinetics in Japanese patients
|
Ueshima, Satoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 148 |
Effect of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on expression of breast cancer resistance protein (BCRP/ABCG2) in human kidney epithelial cell line HK-2
|
Nagai, Junya
|
|
|
61 |
S |
p.
|
artikel
|
| 149 |
Effects of anesthesia and different lymphatic fluid collection methods on the lymphatic transport of orally administered drugs: A comparative study in rats
|
Jiao, Furong
|
|
|
61 |
S |
p.
|
artikel
|
| 150 |
Effects of mefenamic acid on the conjugative metabolism of indole and p-cresol in relation to cellular necrosis in a metabolically competent human hepatoma cell line
|
Kiang, Tony
|
|
|
61 |
S |
p.
|
artikel
|
| 151 |
Effects of MIR-222-3P-mediated downregulation of arylacetamide deacetylase on drug hydrolysis and lipid accumulation
|
Fukami, Tatsuki
|
|
|
61 |
S |
p.
|
artikel
|
| 152 |
Effects of phospholipid type and particle size on lipid nanoparticle distribution in vivo and in pancreatic islets
|
Kanazawa, Takanori
|
|
|
61 |
S |
p.
|
artikel
|
| 153 |
Elucidating mechanisms of promiscuous aggregation on CYP inhibition assays
|
Eng, Heather
|
|
|
61 |
S |
p.
|
artikel
|
| 154 |
Elucidating synergistic risk factors among comorbidity combinations for nephrotic syndrome based on time series statistical evaluation
|
Chida, Katsuyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 155 |
Elucidation of the properties of fatty acid amide hydrolase 2 as a drug-metabolizing enzyme
|
Makino, Chie
|
|
|
61 |
S |
p.
|
artikel
|
| 156 |
Endogenous biomarker-informed approaches for evaluation of transporter-mediated drug-drug and drug-disease interactions
|
Galetin, Aleksandra
|
|
|
61 |
S |
p.
|
artikel
|
| 157 |
Enhanced effect of ionic liquid on intestinal absorption of macromolecules (< 10 kDa)
|
Fukuda, Shoichiro
|
|
|
61 |
S |
p.
|
artikel
|
| 158 |
Enhanced quan/qual approach with software assisted data analysis for tier I soft spot identification in drug discovery
|
Le, Hoa
|
|
|
61 |
S |
p.
|
artikel
|
| 159 |
Enhancing drug-drug interaction prediction by integrating physiologically-based pharmacokinetic model with fraction metabolized by CYP3A4
|
Jiang, Pin
|
|
|
61 |
S |
p.
|
artikel
|
| 160 |
Establishing a physiologically based pharmacokinetic (PBPK) model to simultaneously predict pharmacokinetic variations of irinotecan, SN-38, and SN-38 glucuronide
|
Tanna, Rakshit
|
|
|
61 |
S |
p.
|
artikel
|
| 161 |
Establishment of an air-liquid interface intestinal organoid monolayer and its characterization for drug absorption and metabolism
|
Wehl, Ilona
|
|
|
61 |
S |
p.
|
artikel
|
| 162 |
Establishment of a novel in vitro assay system with CRYPT-derived differentiated intestinal cells to evaluate drug-induced gastrointestinal toxicity caused by the disruption of mucus layer
|
Fukada, Shota
|
|
|
61 |
S |
p.
|
artikel
|
| 163 |
Establishment of DoE-IVIVC model for the pharmacokinetic prediction of ruxolitinib sustained-release dosage forms
|
Shin, Soyoung
|
|
|
61 |
S |
p.
|
artikel
|
| 164 |
Establishment of monkey jejunum CRYPT-derived cells to investigate species difference between monkeys and humans
|
Kusuhara, Hiroyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 165 |
Evaluating transcardial perfusion integrity in brain tissue: Development of a novel hemoglobin quantification assay
|
Hwang, Sangsoo
|
|
|
61 |
S |
p.
|
artikel
|
| 166 |
Evaluation for biotransformation of antibody-peptide conjugates using native mass spectrometry
|
Hagita, Hiraku
|
|
|
61 |
S |
p.
|
artikel
|
| 167 |
Evaluation of a cinnamomum verum product on the pharmacokinetics of the CYP2A6 model drugs nicotine and letrozole in healthy adults
|
Nguyen, Aiden-Hung
|
|
|
61 |
S |
p.
|
artikel
|
| 168 |
Evaluation of acute kidney injury induced by nephrotoxicants using three- dimmensional cultured human proximal tubular epithelial cells
|
Arakawa, Hiroshi
|
|
|
61 |
S |
p.
|
artikel
|
| 169 |
Evaluation of aldehyde-odorant metabolisms and AOX and ALDH expression profiles in human nasal mucosa and mucus
|
Takaoka, Naoki
|
|
|
61 |
S |
p.
|
artikel
|
| 170 |
Evaluation of cytochrome P450 inhibition in the 7-in-1 cocktail using preferred substrates recommend by regulatory agencies
|
Jiang, Lifang
|
|
|
61 |
S |
p.
|
artikel
|
| 171 |
Evaluation of different tissue processing methods in Bama pig skin as an animal model for topical delivery systems
|
Zhang, Chao
|
|
|
61 |
S |
p.
|
artikel
|
| 172 |
Evaluation of in vitro/in silico approach for predicting human absorption parameters after subcutaneous administration of antibodies and Fc-Fusion proteins
|
Yokoyama, Miki
|
|
|
61 |
S |
p.
|
artikel
|
| 173 |
Evaluation of low CL compounds using chimeric mice with humanized liver
|
Suemizu, Hiroshi
|
|
|
61 |
S |
p.
|
artikel
|
| 174 |
Evaluation of receptor-mediated uptake and transcytosis using human ips cell- derived brain microvascular endothelial cells
|
Sato, Hiroyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 175 |
Examining the expression and activity relationship of human hepatic transporters using targeted proteomics
|
Saran, Chitra
|
|
|
61 |
S |
p.
|
artikel
|
| 176 |
Exceeding 100% bioavailability in dog PK: Implication of CYP2D15 polymorphism
|
Zang, Richard
|
|
|
61 |
S |
p.
|
artikel
|
| 177 |
Expanding pharmacogenomics panel assay to include transporter genes and more phase I metabolism variants
|
Blacutt, Jacob
|
|
|
61 |
S |
p.
|
artikel
|
| 178 |
Expending the application of mechanistic static models for regulatory use in predicting CYP- and transporter-mediated drug-drug interactions
|
Barberan, Olivier
|
|
|
61 |
S |
p.
|
artikel
|
| 179 |
Exploring protein-oligonucleotide conjugate lysosomal catabolism: A workflow utilizing liquid chromatography-high resolution mass spectrometry (LC-HRMS) and isocratic labeling technique
|
Zhang, Xin
|
|
|
61 |
S |
p.
|
artikel
|
| 180 |
Exploring the impact of PCB-18 (2,2',5-Trichlorobiphenyl) exposure on hepatic drug metabolizing enzymes and xenobiotic responses in humanzied mice
|
Suh, Youjun
|
|
|
61 |
S |
p.
|
artikel
|
| 181 |
Expression and functional analyses of the PK-related genes in differentiated intestinal epithelial cells derived from cryopreserved human intestinal mucosal epithelium (CHIM)
|
Nakamura, Keiichiro
|
|
|
61 |
S |
p.
|
artikel
|
| 182 |
First-in-human dose estimation for a new composition bee venom, a candidate drug of Alzheimer disease, based on pharmacokinetic interspecies allometric scaling from mice, rats, and beagle dogs
|
Kim, Da Hyun
|
|
|
61 |
S |
p.
|
artikel
|
| 183 |
Food-derived neurotrophic amino acid ergothioneine and its transporter SLC22A4: From bench to healthy food
|
Kato, Yukio
|
|
|
61 |
S |
p.
|
artikel
|
| 184 |
Foreword – Disclaimer
|
|
|
|
61 |
S |
p.
|
artikel
|
| 185 |
Formulation effects on oral APE1/Ref1 inhibitors pharmacokinetics in mice
|
da Silva, Lais
|
|
|
61 |
S |
p.
|
artikel
|
| 186 |
Free fraction comparison method for a highly protein binding compound by dynamic analysis in bi-directional dialysis
|
Igarashi, Fumihiko
|
|
|
61 |
S |
p.
|
artikel
|
| 187 |
Freez converted suspension-type human primary hepatocyte as a novel in vitro model for pharmacokinetic and toxicity assay at an affordable price
|
Shahin, Raghda
|
|
|
61 |
S |
p.
|
artikel
|
| 188 |
Functional characteristics of a newly identified plasma membrane urate transporter
|
Shibutani, Rei
|
|
|
61 |
S |
p.
|
artikel
|
| 189 |
Functional characteristics of a newly identified vesicular membrane-localized monoamine transporter for serotonin transport
|
Matsui, Kaito
|
|
|
61 |
S |
p.
|
artikel
|
| 190 |
Functional characterization of ATP13A3 as a plasma membrane polyamine transporter
|
Morimoto, Haruka
|
|
|
61 |
S |
p.
|
artikel
|
| 191 |
Functional characterization of ENT3/SLC29A3 as a lysosomal urate transporter
|
Matake, Isamu
|
|
|
61 |
S |
p.
|
artikel
|
| 192 |
Functional identification of a lysosomal transporter SLC46A3 as a novel glycoside transporter
|
Tomabechi, Ryuto
|
|
|
61 |
S |
p.
|
artikel
|
| 193 |
Functional identification of disrupted in renal carcinoma 2 (DIRC2/SLC49A4) as a lysosomal exporter for cationic amphiphilic drugs
|
Yasujima, Tomoya
|
|
|
61 |
S |
p.
|
artikel
|
| 194 |
Gastrointestinal imaging with MRI: Insights into the behavior of dosage forms and the conditions at the site of drug release
|
Weitschies, Werner
|
|
|
61 |
S |
p.
|
artikel
|
| 195 |
Generation of in vitro blood-placental barrier (BPB) models using human placental stem cells
|
Hori, Takeshi
|
|
|
61 |
S |
p.
|
artikel
|
| 196 |
Global proteomic profiling of a patient-derived 3D CYST model and reference tissue of polycystic kidney disease
|
Meyer, Alina
|
|
|
61 |
S |
p.
|
artikel
|
| 197 |
Gut bacterial metabolite 3-Phenylpropionic acid inhibits cytochrome P450 2E1 expression and attenuates acetaminophen-induced cytotoxicity in primary mouse hepatocytes
|
Jin, Pei-Ru
|
|
|
61 |
S |
p.
|
artikel
|
| 198 |
Gut microbial metabolites activate pregnane X receptor to increase CYP3A4 expression in the liver
|
Won, Kyoung-Jae
|
|
|
61 |
S |
p.
|
artikel
|
| 199 |
Gut UGT activity loss precedes the development of irinotecan-induced severe diarrhea: Mechanisms, biomaker and prevention
|
Sun, Rongjin
|
|
|
61 |
S |
p.
|
artikel
|
| 200 |
Hepash cells, a novel platform to assess the clearance of low metabolic turnover compounds and CYP induction
|
Tsuruta, Satoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 201 |
Hepatic expression of drug metabolizing enzymes is altered by concomitant obesogenic lipids and alcohol in mice and human hepatic organoids
|
Dempsey, Joseph
|
|
|
61 |
S |
p.
|
artikel
|
| 202 |
High impact application of a continuous learn and confirm PBPK modeling strategy: Evaluating the drug-drug interaction potential for a transglutaminase-2 inhibitor
|
Mudunuru, Jennypher
|
|
|
61 |
S |
p.
|
artikel
|
| 203 |
Highly deep quantitative proteomics elucidate the mechanism of Alzheimers’ disease targeting reactive astrocyte
|
Maeda, Yuki
|
|
|
61 |
S |
p.
|
artikel
|
| 204 |
How do i build an ‘Ideal’ PBPK model if my drug is either a substrate or inducer
|
Asaumi, Ryuta
|
|
|
61 |
S |
p.
|
artikel
|
| 205 |
How do i use PBPK modeling to discern complex drug-drug interactions?
|
Bolleddula, Jayaprakasam
|
|
|
61 |
S |
p.
|
artikel
|
| 206 |
How will CYP induction related PBPK applications be evaluated during the NDA reviews?
|
Wang, Ying-Hong
|
|
|
61 |
S |
p.
|
artikel
|
| 207 |
Human enteroid monolayers – A fit-for purpose model to elucidate intestinal natural product-drug interactions
|
Thummel, Kenneth E.
|
|
|
61 |
S |
p.
|
artikel
|
| 208 |
Identification and characterization of phase II metabolites of resolvins D1 and D5
|
Nogueira, Marina
|
|
|
61 |
S |
p.
|
artikel
|
| 209 |
Identification and validation of selective endogenous substrates of organic anion transporter 1 (OAT1) versus OAT3 using metabolomics and in-vitro mechanistic studies
|
Thakur, Aarzoo
|
|
|
61 |
S |
p.
|
artikel
|
| 210 |
Identification of a novel OATP2B1 substrate by a docking study using AlphaFold2 structure
|
Matsuda, Runa
|
|
|
61 |
S |
p.
|
artikel
|
| 211 |
Identification of drug target engagement of repurposing candidates for polycystic kidney disease by thermal proteome profiling
|
Meyer, Alina
|
|
|
61 |
S |
p.
|
artikel
|
| 212 |
Identification of enzymes responsible for sulindac sulfide S-oxygenation
|
Hashiba, Shiori
|
|
|
61 |
S |
p.
|
artikel
|
| 213 |
Identification of pazopanib as an OATP1B1 substrate by competitive counterflow screeen
|
Huang, Kevin
|
|
|
61 |
S |
p.
|
artikel
|
| 214 |
Identification of physiological factors suppressing colonic drug absorption using quantum imaging technology
|
Yasugi, Yugo
|
|
|
61 |
S |
p.
|
artikel
|
| 215 |
Identification of the major circulating metabolite of MYMD-1 and elucidation of the mechanism of clearance of MYMD-1 in humans. Role of aldehyde oxidase and CYP2A6
|
Kassahun, Kelem
|
|
|
61 |
S |
p.
|
artikel
|
| 216 |
Illustrating the mechanistic absorption and disposition of OATP1B and BCRP probe substrates and the transporter-mediated drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling
|
Chapa, Revathi
|
|
|
61 |
S |
p.
|
artikel
|
| 217 |
Impact of DNA G-Quadruplex formation on CYP3A4 gene transcription
|
Takemoto, Seiya
|
|
|
61 |
S |
p.
|
artikel
|
| 218 |
Impact of G-quadruplex on carboxylesterase 2-dependent drug and lipid metabolism
|
Kuroda, Shintaro
|
|
|
61 |
S |
p.
|
artikel
|
| 219 |
Impact of N-acetyltransferase (NAT) genetic polymorphisms on NAT catalytic activity in human colon mucosa
|
Massey, Thomas
|
|
|
61 |
S |
p.
|
artikel
|
| 220 |
Impact of tyrosine kinases and inhibitors on SGLT1 activity
|
Kharve, Kshitee Sandeep
|
|
|
61 |
S |
p.
|
artikel
|
| 221 |
Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug
|
Gao, Mengxuan
|
|
|
61 |
S |
p.
|
artikel
|
| 222 |
Impairment of hepatic CYP2C and CYP3A activities in the mice treated with fluoropyrimidine anticancer drugs
|
Masubuchi, Yasuhiro
|
|
|
61 |
S |
p.
|
artikel
|
| 223 |
Implementation of blood collection using the Tasso microsampling device to measure thyroid hormone biomarkers
|
Christianson, Chad
|
|
|
61 |
S |
p.
|
artikel
|
| 224 |
Implication of H+/peptide transporters (PEPTS) on uptake of N-lactoylphenylalanine (LAC-PHE) in the intestinal and renal epithelial cells
|
Fujita, Takuya
|
|
|
61 |
S |
p.
|
artikel
|
| 225 |
Improvement of liver function and its long-term maintenance by applying synthetic matrices, hydrox, to primary human hepatocyte-derived organoids and their possible application in hepatotoxicity research
|
Tong, Yanran
|
|
|
61 |
S |
p.
|
artikel
|
| 226 |
Improving ADME properties of therapeutic antibodies by novel engineering technologies
|
Haraya, Kenta
|
|
|
61 |
S |
p.
|
artikel
|
| 227 |
Incorporation of well-stirred, dispersion and parallel tube liver models into simple and permeability limited PBPK frameworks for clearance prediction
|
Nagar, Swati
|
|
|
61 |
S |
p.
|
artikel
|
| 228 |
Induction of drug metabolizing enzymes and transporter genes by carbamazepine, carbamazepine-10,11-Epoxide, and carbamazepine-10,11-diol
|
Lapham, Kimberly
|
|
|
61 |
S |
p.
|
artikel
|
| 229 |
Industrial perspective of reactive metabolites: When to be afraid and when to be very afraid
|
Bauman, Jonathan
|
|
|
61 |
S |
p.
|
artikel
|
| 230 |
Influence of buffer composition on parameterization of liver and kidney scaling factors in rats and mice
|
Doerksen, Michael
|
|
|
61 |
S |
p.
|
artikel
|
| 231 |
Influence of locally bioavailable herbal components on the regulation of gut homoeostatis via expression of intestinal drug metabolizing enzymes and transporters in irinotecan-induced intestinal injury model
|
Saponjac, Vesna Tumbas
|
|
|
61 |
S |
p.
|
artikel
|
| 232 |
Influence of the genetic polymorphism of CYP2D1 on metabolism and pharmacokinetics of E2027 in rats
|
Kasamori, Nana
|
|
|
61 |
S |
p.
|
artikel
|
| 233 |
Integrated transporter elucidation center: Identifying the SLC and ABC proteome in human placenta
|
Fallon, John
|
|
|
61 |
S |
p.
|
artikel
|
| 234 |
Integrating intestinal physiology and drug metabolism, disposition, and interactions through PBPK modeling
|
Prasad, Bhagwat
|
|
|
61 |
S |
p.
|
artikel
|
| 235 |
Intestinal secretion is potentially an important clearance mechanism for highly plasma-bound and low metabolic clearance efflux substrates
|
Subramanian, Murali
|
|
|
61 |
S |
p.
|
artikel
|
| 236 |
Intra-patient variation in CYP2D6 activity over time assessed using the dietary biomarker solanidine in breast cancer patients on tamoxifen
|
Keller, Denise
|
|
|
61 |
S |
p.
|
artikel
|
| 237 |
Investigating the influence of CYP3A and CYP2C8 phenotypes on tucatinib clearance in a diverse cohort of human hepatocyte donors
|
Latham, Bethany
|
|
|
61 |
S |
p.
|
artikel
|
| 238 |
Investigating the role and function of OATP drug transporters in relation to tamoxifen therapy
|
Wong, Michelle
|
|
|
61 |
S |
p.
|
artikel
|
| 239 |
Investigation in the predictive accuracy of brain KPUU across species using in vitro and in vivo methods
|
Zou, Ling
|
|
|
61 |
S |
p.
|
artikel
|
| 240 |
Investigation of creatine pharmacokinetics after chronic oral administration in creatine transporter-deficient mice
|
Tashiro, Naoto
|
|
|
61 |
S |
p.
|
artikel
|
| 241 |
Investigation of OATP1B inhibitory effect by a cyclic peptide using an endogenous biomarker coproporphyrin-I in monkeys
|
Watari, Ryosuke
|
|
|
61 |
S |
p.
|
artikel
|
| 242 |
Investigation of pharmacokinetic properties and brain penetration of genipin: A potential pharmacophore for Parkinson's disease treatment
|
Cho, Hyunjin
|
|
|
61 |
S |
p.
|
artikel
|
| 243 |
Investigation of the mechanism of metronidazole-induced encephalopathy focusing on the possible effect on thiamine transport
|
Yamagishi, Yoshiaki
|
|
|
61 |
S |
p.
|
artikel
|
| 244 |
In vitro assessment of potential for onvansertib to cause cytochrome P450 and transporter-mediated pharmacokinetic drug-drug interactions
|
Shinde, Aparna
|
|
|
61 |
S |
p.
|
artikel
|
| 245 |
In vitro assessment of psilocin for CYP-dependent drug-drug interaction potential using rapid luminescent assays
|
Cali, James
|
|
|
61 |
S |
p.
|
artikel
|
| 246 |
In vitro assessment of the inhibition of human organic anion transporting polypeptide 1B1/1B3 by highly plasma protein bound compounds in the presence of physiological concentration of albumin
|
Zaher, Hani
|
|
|
61 |
S |
p.
|
artikel
|
| 247 |
In vitro evaluation methods for hepatic and renal drug disposition and toxicity
|
Arakawa, Hiroshi
|
|
|
61 |
S |
p.
|
artikel
|
| 248 |
In vitro investigation on inhibition potential of deucravacitinib toward human carboxylesterase (CES) 2
|
Yao, Ming
|
|
|
61 |
S |
p.
|
artikel
|
| 249 |
In vitro - In vivo extrapolation approaches for glucuronidated drugs: Promises and pitfalls
|
Miners, John O.
|
|
|
61 |
S |
p.
|
artikel
|
| 250 |
In vitro mechanistic investigation of unusual clinical drug-drug interaction of trazpiroben on a major reductive metabolite upon rifampin co-administration
|
Nishihara, Mitsuhiro
|
|
|
61 |
S |
p.
|
artikel
|
| 251 |
In vitro metabolism of kobusin in human liver preparations
|
Lee, Min Seo
|
|
|
61 |
S |
p.
|
artikel
|
| 252 |
In vitro plasma or whole blood stability method for ADCS
|
Liu, Haijuan
|
|
|
61 |
S |
p.
|
artikel
|
| 253 |
In vitro study of payload release of an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (ADC-T) and payload metabolism
|
Zhu, Mingshe
|
|
|
61 |
S |
p.
|
artikel
|
| 254 |
In vivo models for assessing the toxicity of reactive metabolites
|
Ding, Xinxin
|
|
|
61 |
S |
p.
|
artikel
|
| 255 |
Involvement of carrier-mediated transport in ribavirin transport at the blood– testis barrier
|
Ito, Takeru
|
|
|
61 |
S |
p.
|
artikel
|
| 256 |
Involvement of efflux transporters ABCG2 and ABCB1 in overall disposition of multikinase inhibitor pazopanib
|
Lumumba, Ruth Shekina
|
|
|
61 |
S |
p.
|
artikel
|
| 257 |
Is the dilution method for measuring IC50 shift values a more sensitive approach for evaluating time-dependent inhibition?
|
Jiang, Lifang
|
|
|
61 |
S |
p.
|
artikel
|
| 258 |
Keyword Index
|
|
|
|
61 |
S |
p.
|
artikel
|
| 259 |
LC-HRMS based kinectic characterization platform for irreversible covalent inhibitor screening
|
Li, Li
|
|
|
61 |
S |
p.
|
artikel
|
| 260 |
Liver humanized chimeric PXB-MOUSE® as a model to predict human renal toxicity by aldehyde oxidase dependent metabolism of SGX-523
|
Johnson, Kevin
|
|
|
61 |
S |
p.
|
artikel
|
| 261 |
Mass balance, pharmacokinetics, and tissue distribution of [14C] Zetomipzomib in rats by quantitative whole-body autoradiography
|
Wang, Jinhai
|
|
|
61 |
S |
p.
|
artikel
|
| 262 |
Mass balance recovery, absorption, metabolism, and excretion of [14C]-Acoziborole in healthy male subjects after single microtracer oral dosing – III – Investigation of metabolite profile in plasma, urine and fecal homogenate samples using UPLC-MS FRACTI
|
Shaw, Iain
|
|
|
61 |
S |
p.
|
artikel
|
| 263 |
Mass balance recovery, absorption, metabolism, and excretion of [14C]-Acoziborole in healthy male subjects after single microtracer oral dosing – I – Preparation of GMP [14C]- acoziborole drug substance
|
Carver, David
|
|
|
61 |
S |
p.
|
artikel
|
| 264 |
Mass balance recovery, absorption, metabolism and excretion of [14C]-Acoziborole in healthy male subjects after single oral dosing - II - mass balance and clinical safety assessments
|
Shaw, Iain
|
|
|
61 |
S |
p.
|
artikel
|
| 265 |
MATE are bound to a multiprotein complex containing NHE3, and it's causing functional interactions
|
Goda, Mitsuhiro
|
|
|
61 |
S |
p.
|
artikel
|
| 266 |
Maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes epigenetic effects: Possible mechanism based on whole-genome methylation analysis
|
Fujimoto, Mana
|
|
|
61 |
S |
p.
|
artikel
|
| 267 |
Mechanism by which AADAC regulates hepatic lipid level in vivo
|
Nagaoka, Mai
|
|
|
61 |
S |
p.
|
artikel
|
| 268 |
Mechanisms underlying altered drug clearance in pregnancy
|
Fashe, Muluneh
|
|
|
61 |
S |
p.
|
artikel
|
| 269 |
Mechanisms underlying cognitive enhancement induced by oral ingestion of yeast- derived RNA using comprehensive targeted lipidomics
|
Hayashi, Fuyu
|
|
|
61 |
S |
p.
|
artikel
|
| 270 |
Mechanistic multiple parameter optimization in drug discovery
|
Broccatelli, Fabio
|
|
|
61 |
S |
p.
|
artikel
|
| 271 |
Mechanistic studies supporting the evaluation of pharmacokinetic-drug interactions with drugs approved by the U.S. food and drug administration in 2023: A systematic review of new drug applications
|
Yu, Jingjing
|
|
|
61 |
S |
p.
|
artikel
|
| 272 |
Membrane transporters in drug development and as determinants of precision medicine; an update from the international transporter consortium
|
Brouwer, Kim
|
|
|
61 |
S |
p.
|
artikel
|
| 273 |
Metabolic flux analysis unveiled tissue- and sex-specific tryptophan metabolism in a gut microbiome dependent manner in humanized PXR-transgenic mouse
|
Kim, Sarah
|
|
|
61 |
S |
p.
|
artikel
|
| 274 |
Metabolic stability assessment of the tau PET tracer [18F] GTP1
|
Rich, Sharyl
|
|
|
61 |
S |
p.
|
artikel
|
| 275 |
Metabolism and excretion of the adenosine A2A/A2B receptor inhibitor, [14C]- Etrumadenant, in humans
|
Zhu, Yanlin
|
|
|
61 |
S |
p.
|
artikel
|
| 276 |
Metabolism of pirocarpine in chimeric mice with humanized liver
|
Uehara, Shotaro
|
|
|
61 |
S |
p.
|
artikel
|
| 277 |
Metabolism of zastaprazan in human and animal hepatocytes
|
Lee, Min Seo
|
|
|
61 |
S |
p.
|
artikel
|
| 278 |
Metabolite profiling and identification of GIPR peptide 1: A dual-[14C] labeled lipid- conjugated peptide in dog plasma, urine, and feces
|
Guo, Yukuang
|
|
|
61 |
S |
p.
|
artikel
|
| 279 |
Metabolite profiling of [14C]BMS-986166 and its active metabolite (BMS-986166-P) following a single oral dose to intact/bile duct cannulated rats
|
Chen, Weiqi
|
|
|
61 |
S |
p.
|
artikel
|
| 280 |
Microfluidic chip for construction of 3D microvascular network of blood-brain barrier
|
Fujita, Satoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 281 |
Mitigating strategy for drug induced liver injury LED by reactive metabolites
|
Zhu, Sean
|
|
|
61 |
S |
p.
|
artikel
|
| 282 |
Model-based exploration of parent-metabolite kinetics of MT-202: Nonclinical characterization and feasibility of clinical metabolite exposure prediction
|
Sun, Austin
|
|
|
61 |
S |
p.
|
artikel
|
| 283 |
Model-based meta-analysis of ethnic differences - General changes in clearance by pathways and aging
|
Hisaka, Akihiro
|
|
|
61 |
S |
p.
|
artikel
|
| 284 |
Modeling and simulation reveals the impact of binding affinity (Kd) on target-mediated disposition: A case study of lumretuzumab
|
Saravanakumar, Anitha
|
|
|
61 |
S |
p.
|
artikel
|
| 285 |
Monkey blood-brain barrier co-culture model as an alternative method for predicting brain penetration
|
Kanki, Satomi
|
|
|
61 |
S |
p.
|
artikel
|
| 286 |
Monkey CYP2C8-mediated formation of rearranged metabolites of the selective Nav1.7 inhibitor DS-1971a
|
Michiba, Kazuyoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 287 |
Monocarboxylate transporters 8 and 10: Siblings with different personalities
|
Rodriguez, Acilegna
|
|
|
61 |
S |
p.
|
artikel
|
| 288 |
Moxidectin metabolism in reindeer
|
Ivanova, Lada
|
|
|
61 |
S |
p.
|
artikel
|
| 289 |
Mucoadhesive hemi-porous Janus microparticles: Potential formulation to improve intestinal absorption for BCS Class 3 drugs
|
Matsumoto, Akihiro
|
|
|
61 |
S |
p.
|
artikel
|
| 290 |
Multicellular spheroidal human blood-brain barrier models are a useful tool for characterization of brain-penetrating antibodies
|
Ohki, Seiya
|
|
|
61 |
S |
p.
|
artikel
|
| 291 |
Next generation quantitative proteomics-based central nervous system barrier studies
|
Uchida, Yasuo
|
|
|
61 |
S |
p.
|
artikel
|
| 292 |
Niemann-pick C1-like 1 regulates in vivo behaviors of sphingolipids
|
Yamanashi, Yoshihide
|
|
|
61 |
S |
p.
|
artikel
|
| 293 |
Non-targeted metabolomics for the identification of biomarker candidates for breast cancer resistance protein
|
Niemi, Mikko
|
|
|
61 |
S |
p.
|
artikel
|
| 294 |
Novel bioengineered RNA molecules for the study of gene regulation in drug and nutrient transport and metabolism
|
Tu, Meijuan
|
|
|
61 |
S |
p.
|
artikel
|
| 295 |
Novel mechanisms of drug-metabolizing hydrolases regulating the toxicity caused by reactive metabolites
|
Fukami, Tatsuki
|
|
|
61 |
S |
p.
|
artikel
|
| 296 |
Nuclear receptor PPARγ is a potent regulator of GPNMB gene in the fatty liver
|
Aibara, Daisuke
|
|
|
61 |
S |
p.
|
artikel
|
| 297 |
Oligonucleotide target engagement
|
McCoy, Michael
|
|
|
61 |
S |
p.
|
artikel
|
| 298 |
OMICS data-based analysis of mitochondrial characteristics and toxicity mechanisms
|
Hamada, Kazuma
|
|
|
61 |
S |
p.
|
artikel
|
| 299 |
Optimization of linker sequence of aminopeptidase A-Fc fusion proteins in pharmacokinetics and antihypertensive effect
|
Yamaguchi, Yukiko
|
|
|
61 |
S |
p.
|
artikel
|
| 300 |
Optimization of oral dose of 3-hydroxybutyrate based on pharmacokinetic modeling for cognitive function and mood
|
Nishioka, Kentaro
|
|
|
61 |
S |
p.
|
artikel
|
| 301 |
PBPK modeling of drug-drug interactions between antiandrogens and HIV medicines
|
Chen, Kuan-Fu
|
|
|
61 |
S |
p.
|
artikel
|
| 302 |
Pegylated testosterone with enhanced pharmacokinetic properties in mice
|
Lee, Chae Bin
|
|
|
61 |
S |
p.
|
artikel
|
| 303 |
Pharmacokinetic and pharmacodynamic interactions between astragalus membranaceus polysaccharides and metformin in diabetic mice
|
Zuo, Zhong
|
|
|
61 |
S |
p.
|
artikel
|
| 304 |
Pharmacokinetic evaluation of neutral-sphinghomyelinase2 (nSMase2) inhibitor prodrugs in dogs
|
Ranjit, Arina
|
|
|
61 |
S |
p.
|
artikel
|
| 305 |
Pharmacokinetic interactions of niclosamide in rats: Involvement of organic anion transporters 1 and 3 and organic cation transporter 2
|
Kim, MinJu
|
|
|
61 |
S |
p.
|
artikel
|
| 306 |
Pharmacokinetic modeling leveraging in vitro to in vivo extrapolation of the gut microbiome’s role in sulfasalazine metabolism into sulfapyridine and mesalamine
|
Cheng, Lisa
|
|
|
61 |
S |
p.
|
artikel
|
| 307 |
Pharmacokinetics comparison between pressurized intraperitoneal aerosolized chemotherapy (PIPAC) and intravenous infusion of oxaliplatin in pig plasma and tissues
|
Kim, Duk Yeon
|
|
|
61 |
S |
p.
|
artikel
|
| 308 |
Pharmacokinetics of monoclonal antibodies locally-applied into the middle ear of guinea pigs
|
Kita, Tomoko
|
|
|
61 |
S |
p.
|
artikel
|
| 309 |
Phenotyping assay using genetically manipulated human IPS cell-derived hepatocyte- like cells
|
Mizuguchi, Hiroyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 310 |
Physicochemical characterization of particulate matter from a coal-fired power plant and the toxicological profile in BALB/C mice
|
Techapichetvanich, Pinnakarn
|
|
|
61 |
S |
p.
|
artikel
|
| 311 |
Physiologically based biopharmaceutics modelling of the effect of a permeability enhancer on the absorption of a highly soluble and poorly permeable small peptide in humans
|
Diaz de Leon Ortega, Ricardo
|
|
|
61 |
S |
p.
|
artikel
|
| 312 |
Physiologically based pharmacokinetic analysis of the impact of controlled- release formulations on oral absorption of CYP3A4 substrates using modified iliad model
|
Murayama, Emika
|
|
|
61 |
S |
p.
|
artikel
|
| 313 |
Physiologically based pharmacokinetic modeling of cannabidiol (CBD), Δ-9- tetrahydrocannabinol (THC), and their active metabolites in healthy adults after administration of CBD and THC by multiple routes
|
Zhou, Zhu
|
|
|
61 |
S |
p.
|
artikel
|
| 314 |
Plasma concentration of LAT1 substrate amino acids affects the spinal cord transfer and the analgesic effect of pregabalin
|
Akashi, Tomoya
|
|
|
61 |
S |
p.
|
artikel
|
| 315 |
Plasma protein binding determination challenges and solutions for very highly protein bound drugs: Case study of cilofexor and its metabolites with clinical applications
|
Xiao, Deqing
|
|
|
61 |
S |
p.
|
artikel
|
| 316 |
PM2.5 engages impairment of mucosal immunity, involving alteration of complement activation and cell junction assembly by regulated IL-17 levels: Pathological and proteomic approaches
|
Palpai, Warat
|
|
|
61 |
S |
p.
|
artikel
|
| 317 |
Population pharmacokinetics of ceftriaxone in Japanese patients with hemodialysis
|
Tohi, Makiko
|
|
|
61 |
S |
p.
|
artikel
|
| 318 |
Potential drug–drug interactions of frequently prescribed medications in elderly people with osteoporosis and non-communicable diseases, and a comparison with real- world practice
|
Suechanyapong, Werapat
|
|
|
61 |
S |
p.
|
artikel
|
| 319 |
Potential transporter-mediated HERB-drug interactions of Zingiber officinale and uncaria tomentosa
|
Szilvasy, Nora
|
|
|
61 |
S |
p.
|
artikel
|
| 320 |
Preclinical DDI risk assessment in drug discovery and development
|
Hariparsad, Niresh
|
|
|
61 |
S |
p.
|
artikel
|
| 321 |
Predicting clinical ADME parameters with multi-tissue chip platform using primary human cells
|
Rajan, Shiny
|
|
|
61 |
S |
p.
|
artikel
|
| 322 |
Prediction of drug intestinal absorption and toxicity with the use of human/animal CRYPT-derived cultured intestinal cells
|
Maeda, Kazyua
|
|
|
61 |
S |
p.
|
artikel
|
| 323 |
Prediction of human effective dose and pharmacokinetics-pharmacodynamics using preclinical data
|
Lim, Sunyoung
|
|
|
61 |
S |
p.
|
artikel
|
| 324 |
Prediction of intestinal availability of CYP3A and UGT substrate drugs from in vitro assay with differentiated intestinal cells derived from cryopreserved human small intestinal mucosa (CHIM)
|
Sugawara, Chiaki
|
|
|
61 |
S |
p.
|
artikel
|
| 325 |
Prediction of the in vivo pharmacokinetics of sustained-release injections for semaglutide by a novel ivivc model combined with DoE
|
Kim, Joonhee
|
|
|
61 |
S |
p.
|
artikel
|
| 326 |
Pre-systemic metabolism of EMIQ, a potential therapeutic for myotonic dystrophy type 1, in human intestinal S9
|
Saravanan Vanaja, Purnajai Srivijay
|
|
|
61 |
S |
p.
|
artikel
|
| 327 |
Primary culture of rat kidney tissue slice for evaluation of drug-induced kidney injury using gas-permeable plates
|
Kadoguchi, Moeno
|
|
|
61 |
S |
p.
|
artikel
|
| 328 |
Primary human intestinal cell model for estimating drug absorption, efflux and metabolism
|
Cheong, Jonathan
|
|
|
61 |
S |
p.
|
artikel
|
| 329 |
Production and use of recombinant mirnas to dissect the intrinsic differences in miRNA biogenesis and regulation of drug metabolism and disposition
|
Tu, Meijuan
|
|
|
61 |
S |
p.
|
artikel
|
| 330 |
Proposed workflow to weed out potential DILI-positive test articles
|
Mukkavilli, Rao
|
|
|
61 |
S |
p.
|
artikel
|
| 331 |
Protac tissue distribution
|
Steyn, Stefanus
|
|
|
61 |
S |
p.
|
artikel
|
| 332 |
Protective effects of omeprazole against oxaliplatin-induced peripheral neuropathy via OCTN transporter-mediated mechanisms in a rodent model
|
Tsukushi, Yasuhito
|
|
|
61 |
S |
p.
|
artikel
|
| 333 |
Protein abundance of hydrolytic drug metabolizing enzymes in different tissues and across species
|
Subash, Sandhya
|
|
|
61 |
S |
p.
|
artikel
|
| 334 |
Protein expression as endpoint for assessment of CYP2B6 induction: Application of immuno-affinity capture method reveals improved dynamic response range
|
Enoru, Julius
|
|
|
61 |
S |
p.
|
artikel
|
| 335 |
Protein-mediated uptake effect and its implications for OATP1B1/1B3-mediated drug- drug interactions investigations
|
Parvez, Md Masud
|
|
|
61 |
S |
p.
|
artikel
|
| 336 |
Quantification and visualization of OATP1B1 expression in in vitro uptake system for risk assessment of DDI
|
Ohtsu, Naoko
|
|
|
61 |
S |
p.
|
artikel
|
| 337 |
Quantitative analysis of antibody conjugate payload by LC MS/MS without immunocapture
|
Zhang, Suhong
|
|
|
61 |
S |
p.
|
artikel
|
| 338 |
Quantitative analysis of gastrointestinal drug absorption and disposition using state-of-the-art technology
|
Shirasaka, Yoshiyuki
|
|
|
61 |
S |
p.
|
artikel
|
| 339 |
Quantitative analysis of oligonucleotide by ion paring reversed-phase LC-MS/MS
|
Yang, Suhong
|
|
|
61 |
S |
p.
|
artikel
|
| 340 |
Quantitative analysis of the impact of C421A mutation on BCRP activity in human ileal CRYPT-derived differentiated cells
|
Namai, Mana
|
|
|
61 |
S |
p.
|
artikel
|
| 341 |
Quantitative prediction of P-GP/CYP3A substrate drug absorption in humans using a monolayer model derived from intestinal organoids
|
Mochizuki, Tatsuki
|
|
|
61 |
S |
p.
|
artikel
|
| 342 |
Quantitative proteomics-based identification of novel thrapeutic targets for progressive supranuclear palsy using post-mortem human brain
|
Kumagai, Yuta
|
|
|
61 |
S |
p.
|
artikel
|
| 343 |
Radiation therapy for brain tumors: Does it influence drug delivery?
|
Zhang, Wenjuan
|
|
|
61 |
S |
p.
|
artikel
|
| 344 |
Radiokinetics, pharmacokinetics, mass balance and excretion, and metabolism of radiolabeled PROTAC® androgen receptor degrader bavdegalutamide (ARV-110) following intravenous and oral administration in rats
|
Zhang, George
|
|
|
61 |
S |
p.
|
artikel
|
| 345 |
Rapid adenosine bioanalysis with LS-LC-MS/MS
|
Li, Xiaotong
|
|
|
61 |
S |
p.
|
artikel
|
| 346 |
Rapid determination of lipophilicity: Exploration and establishment of reversed- phase liquid chromatography (RPLC) methods
|
Cheng, Liwei
|
|
|
61 |
S |
p.
|
artikel
|
| 347 |
Rapid production of rabbit monoclonal anti-idiotype antibody for antibody drugs by ecobody technology
|
Kawano, Shin
|
|
|
61 |
S |
p.
|
artikel
|
| 348 |
Rat and dog quad-culture liver chip models: Characterization and use to interrogate a potential flavin-containing monooxygenase-mediated, species-specific toxicity of a histamine receptor antagonist
|
Stresser, David
|
|
|
61 |
S |
p.
|
artikel
|
| 349 |
Regulation of glycolysis in CD8+ T cells determines the susceptibility to HLA-mediated abacavir-induced skin toxicity
|
Susukida, Takeshi
|
|
|
61 |
S |
p.
|
artikel
|
| 350 |
Regulation of P-glycoprotein expression and role of ERM proteins in lung cancer cell metastasis
|
Liu, Wangyang
|
|
|
61 |
S |
p.
|
artikel
|
| 351 |
Regulation of rat hepatic monocarboxylate transporter expression by sex and cross-sex hormone treatment
|
Zhang, Qing
|
|
|
61 |
S |
p.
|
artikel
|
| 352 |
Regulatory acceptance of MPS - Consideration from context of USE
|
Ishida, Seiichi
|
|
|
61 |
S |
p.
|
artikel
|
| 353 |
Review of finalized ICH M12 guideline on drug interaction studies
|
Ishiguro, Akihiro
|
|
|
61 |
S |
p.
|
artikel
|
| 354 |
Role of intestinal transporters in regional absorption kinetics and intricate pharmacokinetic profiles of talinolol
|
Ishida, Kazuya
|
|
|
61 |
S |
p.
|
artikel
|
| 355 |
Role of intracellular SLC46A3 in the cytosolic exposure and pharmacological effect of the payload of trastuzumab emtansine (ADC)
|
Inoue, Katsuhisa
|
|
|
61 |
S |
p.
|
artikel
|
| 356 |
Roles of NOLC1 in nuclear translocation of PXR
|
Nagaoka, Kyoka
|
|
|
61 |
S |
p.
|
artikel
|
| 357 |
Schisandra sphenanthera: Its hepatoprotection and beyond
|
Bi, Huichang
|
|
|
61 |
S |
p.
|
artikel
|
| 358 |
Screening methods comparison of the effect of pharmaceutical excipients on drug permeability
|
Morita, Tokio
|
|
|
61 |
S |
p.
|
artikel
|
| 359 |
Screening of an FDA-approved drug library to identify organic anion transporter 4 inhibitors
|
Ohashi, Haruki
|
|
|
61 |
S |
p.
|
artikel
|
| 360 |
Screening of renal plasma flow biomarker based on untargeted metabolomics analysis
|
Suzaki, Tomoko
|
|
|
61 |
S |
p.
|
artikel
|
| 361 |
Screening towards a CYP3A7-specific marker reaction against CYP3A4 and CYP3A5
|
Padilha, Elias Carvalho
|
|
|
61 |
S |
p.
|
artikel
|
| 362 |
SDS-stable homo-oligomers of UDP-Glucuronosyltransferase 2B7: Involvement of disulfide bond formation via a specific cystein residue
|
Miyauchi, Yuu
|
|
|
61 |
S |
p.
|
artikel
|
| 363 |
Selection of liver models of hepatic drug clearance: Improvements and implications for ivive and PBPK modeling
|
Pang, K. Sandy
|
|
|
61 |
S |
p.
|
artikel
|
| 364 |
Separate evaluation of systemic circulation transition and biliary excretion of drug metabolites using a novel in vitro cultured hepatocyte system icHep
|
Nakazono, Yuya
|
|
|
61 |
S |
p.
|
artikel
|
| 365 |
Simultaneous determination of 7 bio-toxins(Peptide type) in fishes by UPLC-MS/MS
|
Han, Songyi
|
|
|
61 |
S |
p.
|
artikel
|
| 366 |
Simultaneous determination of lanosterol and its major metabolite FF-MAS in biological samples by liquid chromatography–tandem mass spectrometry
|
Gu, Qi
|
|
|
61 |
S |
p.
|
artikel
|
| 367 |
Solanidine metabolites as dietary CYP2D6 biomarkers of tamoxifen metabolism
|
Medwid, Samantha
|
|
|
61 |
S |
p.
|
artikel
|
| 368 |
Species specificity and selection of animal models for drug oxygenations differently contributed by polymorphic human enzymes
|
Yamazaki, Hiroshi
|
|
|
61 |
S |
p.
|
artikel
|
| 369 |
Species-specific plasma matrix matching for mist coverage determination
|
Freiberger, Elyse
|
|
|
61 |
S |
p.
|
artikel
|
| 370 |
Stability testing and metabolite profiling to support optimization of cyclic peptides for oral delivery
|
Iyer, Ramaswamy
|
|
|
61 |
S |
p.
|
artikel
|
| 371 |
Study on enhanced glucose excretion in Caco2 cells by metformin using asymmetric lipid nanoparticles
|
Kitazawa, Takeo
|
|
|
61 |
S |
p.
|
artikel
|
| 372 |
Survey on pharmacodynamic marker usages in biosimilar development and evaluation
|
Saito, Yoshiro
|
|
|
61 |
S |
p.
|
artikel
|
| 373 |
Systematic evaluation of underlying models that improve purely in-silico high- throughput mechanistic PBPK predictions across species
|
Jones, Jeremy
|
|
|
61 |
S |
p.
|
artikel
|
| 374 |
Targeted Protein Degraders (TPD): PK/PD translation from preclinical to clinical
|
Chen, Dapeng
|
|
|
61 |
S |
p.
|
artikel
|
| 375 |
Taurine transport mechanism in an in vitro human blood-brain barrier model cell line
|
Tega, Yuma
|
|
|
61 |
S |
p.
|
artikel
|
| 376 |
The application of Kirchhoff's Laws to saturable, michaelis-menten, pharmacokinetics
|
Benet, Leslie
|
|
|
61 |
S |
p.
|
artikel
|
| 377 |
The blood brain barrier demonstrates capability to influence heterogenous tenofovir and emtricitabine metabolism and transport in the brain
|
Wilkins, Hannah
|
|
|
61 |
S |
p.
|
artikel
|
| 378 |
The gut microbiome regulates hepatic drug processing genes in livers of humanized PXR-CAR-CYP3A4/3A7 mice
|
Liem, Jennifer
|
|
|
61 |
S |
p.
|
artikel
|
| 379 |
The impact of glucose levels on efficacy of the FDA-approved antisense oligonucleotide drugs
|
Giang Nguyen, Le Tra
|
|
|
61 |
S |
p.
|
artikel
|
| 380 |
The impact of uptake and efflux transporters on the disposition and cholesterol lowing effect of ezetimibe
|
Du, Ting
|
|
|
61 |
S |
p.
|
artikel
|
| 381 |
The importance for determining plasma/tissue concentrations and highly sensitive bioanalytical methods to understand relationship between exposure and efficacy of phosphorodiamidate morpholino oligonucleotides
|
Kameyama, Tsubasa
|
|
|
61 |
S |
p.
|
artikel
|
| 382 |
The influence of alpha-1 acid glycoprotein binding on total plasma free fraction and the effect on clinical pharmacokinetics
|
Wang, Kelly
|
|
|
61 |
S |
p.
|
artikel
|
| 383 |
The influence of ethnic difference on simvastatin and its metabolite pharmacokinetics
|
Srimatimanon, Thanate
|
|
|
61 |
S |
p.
|
artikel
|
| 384 |
The investigation of the metabolism and disposition mechanism of buprenorphine and its analogs
|
Chen, Jie
|
|
|
61 |
S |
p.
|
artikel
|
| 385 |
The in vivo pharmacokinetics of cross-linking antisense-modified nucleic acids radiolabeled by FT-labelling method
|
Kikuchi, Takahiro
|
|
|
61 |
S |
p.
|
artikel
|
| 386 |
The mass balance, recovery, absorption, metabolism, and excretion of [14C]- Mirdametinib in healthy male participants after oral dosing
|
Baughman, Todd
|
|
|
61 |
S |
p.
|
artikel
|
| 387 |
The ontogeny and inter-individual variability of hydrolytic drug-metabolizing enzymes in human liver
|
Singh, Dilip
|
|
|
61 |
S |
p.
|
artikel
|
| 388 |
The psychotropic botanicals Kratom and hemp induce select cytochrome P450 enzymes in human hepatocytes: Inhibition is not the only game in town
|
Hao, Tianran
|
|
|
61 |
S |
p.
|
artikel
|
| 389 |
The regulatory roles of the lncRNA HNF1AOS1 in hepatic drug metabolism in mice
|
Armanios, Beshoy
|
|
|
61 |
S |
p.
|
artikel
|
| 390 |
The site-selective tritium labeling of modified nucleic acids using functionality transfer reaction for pharmacokinetic studies
|
Takahashi, Norihito
|
|
|
61 |
S |
p.
|
artikel
|
| 391 |
Thinking beyond cytochrome P450 inactivation kinetics: Enhanced understanding of the mechanism of tucatinib interaction with CYP3A4
|
Abdelhamed, Mostafa
|
|
|
61 |
S |
p.
|
artikel
|
| 392 |
Tips for bioanalytical method development of peptides, and their DDI risk evaluation
|
Saito, Kosuke
|
|
|
61 |
S |
p.
|
artikel
|
| 393 |
Tissue pharmacokinetic-pharmacodynamic analysis of PH-responsive doxorubicin- releasing micelles with anticancer effect
|
Yamashita, Shugo
|
|
|
61 |
S |
p.
|
artikel
|
| 394 |
Title page
|
|
|
|
61 |
S |
p.
|
artikel
|
| 395 |
TLC-2716, a novel Liver X Receptor (LXR) inverse agonist with high enterohepatic but low systemic exposure
|
Murakami, Eisuke
|
|
|
61 |
S |
p.
|
artikel
|
| 396 |
To be there or not to be there: Does presence of human OATP2B1 impact CYP3A expression?
|
Schaefer, Anima
|
|
|
61 |
S |
p.
|
artikel
|
| 397 |
TOC
|
|
|
|
61 |
S |
p.
|
artikel
|
| 398 |
Towards a pharma[e]cological view of precision medicine
|
Turnbaugh, Peter
|
|
|
61 |
S |
p.
|
artikel
|
| 399 |
Translational pharmacokinetic-pharmacodynamic/toxicodynamic (PK-PD/TD) modeling of antitumor effects and peripheral neuropathy in gemcitabine and NAB-paclitaxel chemotherapy
|
Kobuchi, Shinji
|
|
|
61 |
S |
p.
|
artikel
|
| 400 |
Transport characteristics of extracellular vesicles derived from human trophoblast stem cells in human blood-brain barrier endothelial cells
|
Shimizu, Toshiki
|
|
|
61 |
S |
p.
|
artikel
|
| 401 |
Trends in in vitro potency and PK parameters; can therapeutic doses be estimated from in vitro KI?
|
Tsuchitani, Toshiaki
|
|
|
61 |
S |
p.
|
artikel
|
| 402 |
Triggering of paclitaxel release from PEG monoglyceride niosomes by empty Span85 niosomes
|
Ogawara, Ken-ichi
|
|
|
61 |
S |
p.
|
artikel
|
| 403 |
Uncovering Target-Mediated Drug Disposition (TMDD) of small molecule brain penetrant EBP inhibitors
|
Salphati, Laurent
|
|
|
61 |
S |
p.
|
artikel
|
| 404 |
Unexpected major circulating metabolite M219 detected in 14C-labeled human adme study of brilaroxazine
|
Shen, Li
|
|
|
61 |
S |
p.
|
artikel
|
| 405 |
Unraveling cannabinoids-drug interactions in aging: Insights from PBPK modeling
|
Zhou, Zhu
|
|
|
61 |
S |
p.
|
artikel
|
| 406 |
Unraveling the impact of metabolic dysfunction-associated steatohepatitis on the therapeutic efficacy of FDA-approved siRNA drugs
|
Tawfik, Sherouk
|
|
|
61 |
S |
p.
|
artikel
|
| 407 |
Unraveling the role of HNF1A-AS1 in hepatocyte maturation and subnuclear spaces organization
|
Jin, Jing
|
|
|
61 |
S |
p.
|
artikel
|
| 408 |
Unveiling the mechanistic involvement of the human microbiome and human drug- processing genes in modulating the hepatic transcriptome in mice in vivo
|
Lim, Joe Jongpyo
|
|
|
61 |
S |
p.
|
artikel
|
| 409 |
Update from the IQ TALG quantitative fraction metabolized working group
|
Doran, Angela
|
|
|
61 |
S |
p.
|
artikel
|
| 410 |
Using high-resolution mass spectrometry and software aided metabolite assessment for cytochrome P450 reaction phenotyping of low clearance small molecule drugs
|
Johnson, Kevin
|
|
|
61 |
S |
p.
|
artikel
|
| 411 |
Using intestinal microsomes to assess the impact of gut metabolism on the intestinal absorption of BIDAC degraders
|
Singh, Ritu
|
|
|
61 |
S |
p.
|
artikel
|
| 412 |
Utility of mechanistic static models for predicting CYP- and transporter-mediated DDI
|
Peters, Sheila
|
|
|
61 |
S |
p.
|
artikel
|
| 413 |
Utilizing patient-derived tumoroids as a screening platform for evaluating cell- based immunotherapies in solid tumors
|
Wallace, Gillian
|
|
|
61 |
S |
p.
|
artikel
|
| 414 |
Utilizing PBPK modeling and in vitro data for predicting complex DDIS of OATP1B and CYP substrates caused by various perpetrators
|
Sugiyama, Yuichi
|
|
|
61 |
S |
p.
|
artikel
|
| 415 |
Validation of LC-MS/MS method for the quantification of dehydroepiandrosterone sulfate (DHEAS) and phase-2 metabolites of several hormones in rat’s plasma, and bile samples
|
Srinual, Songpol
|
|
|
61 |
S |
p.
|
artikel
|
| 416 |
Validation of QPCR method to detect human cells in mouse and rat tissues
|
Abe, Kuniyoshi
|
|
|
61 |
S |
p.
|
artikel
|
| 417 |
Why and when do i use PBPK modeling
|
Taskar, Kunal
|
|
|
61 |
S |
p.
|
artikel
|
| 418 |
Xenobiotic transporter SLC22A4 expressed in microglia and neuron as a potential target for neurogenesis in Alzheimer's disease model mice
|
Yamashita, Reiya
|
|
|
61 |
S |
p.
|
artikel
|
Tijdschrift beschrijving